Literature DB >> 27815790

Keratoconus and Other Corneal Diseases: Pharmacologic Cross-Linking and Future Therapy.

Kimberly M Hsu1, Joel Sugar2.   

Abstract

The ability to cross-link collagen fibers and use this technique to strengthen the cornea has become of great interest to ophthalmologists in the last decade. For progressive diseases such as keratoconus, collagen cross-linking confers the possibility of halting progression and stabilizing the cornea, a benefit that is not observed with any other current treatment. Collagen cross-linking uses riboflavin combined with ultraviolet A light to induce the formation of bonds between collagen fibrils that strengthen the cornea. This chapter will discuss the theory, technique, indications, and complications of corneal cross-linking. Much of what will be discussed is in areas of active research that will likely be further clarified as more experience is gained with this procedure.

Entities:  

Keywords:  Collagen cross-linking; Cornea; Keratoconus

Mesh:

Substances:

Year:  2017        PMID: 27815790     DOI: 10.1007/164_2016_23

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  3 in total

Review 1.  Role of corneal collagen fibrils in corneal disorders and related pathological conditions.

Authors:  Hong-Yan Zhou; Yan Cao; Jie Wu; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

2.  Effectiveness of voriconazole and corneal cross-linking on Phialophora verrucosa keratitis: a case report.

Authors:  Marisa Taechajongjintana; Ngamjit Kasetsuwan; Usanee Reinprayoon; Sirinuch Sawanwattanakul; Phattrawan Pisuchpen
Journal:  J Med Case Rep       Date:  2018-08-19

3.  Model Systems for Evidencing the Mediator Role of Riboflavin in the UVA Cross-Linking Treatment of Keratoconus.

Authors:  Mihaela Monica Constantin; Cătălina Gabriela Corbu; Sorin Mocanu; Elena Irina Popescu; Marin Micutz; Teodora Staicu; Raluca Şomoghi; Bogdan Trică; Vlad Tudor Popa; Aurica Precupas; Iulia Matei; Gabriela Ionita
Journal:  Molecules       Date:  2021-12-29       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.